Immunocore (IMCR) to Release Earnings on Thursday

Immunocore (NASDAQ:IMCR) is expected to be posting its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect Immunocore to post earnings of ($0.01) per share and revenue of $146.6880 million for the quarter. Individuals are encouraged to explore the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Monday, August 10, 2026 at 2:00 AM ET.

Immunocore (NASDAQ:IMCR) last released its quarterly earnings data on Wednesday, May 6th. The company reported $0.25 EPS for the quarter, beating the consensus estimate of ($0.26) by $0.51. Immunocore had a negative net margin of 6.68% and a negative return on equity of 7.07%. The business had revenue of $106.68 million during the quarter, compared to analyst estimates of $145.20 million. During the same quarter last year, the business earned $0.10 earnings per share. Immunocore’s quarterly revenue was up 13.6% compared to the same quarter last year. On average, analysts expect Immunocore to post $0 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Immunocore Stock Performance

Immunocore stock opened at $33.42 on Thursday. The company’s 50-day moving average price is $31.01 and its 200-day moving average price is $31.30. Immunocore has a twelve month low of $27.56 and a twelve month high of $40.71. The company has a quick ratio of 4.15, a current ratio of 4.18 and a debt-to-equity ratio of 1.00. The company has a market cap of $1.70 billion, a PE ratio of -60.76 and a beta of 0.73.

Analysts Set New Price Targets

Several research analysts recently commented on the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of Immunocore in a research report on Friday, July 17th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Immunocore in a research note on Monday, July 13th. Wall Street Zen downgraded Immunocore from a “buy” rating to a “hold” rating in a research report on Tuesday. Zacks Research downgraded Immunocore from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 7th. Finally, HC Wainwright reiterated a “buy” rating and set a $100.00 price objective on shares of Immunocore in a research report on Monday, April 20th. Five investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Immunocore presently has a consensus rating of “Hold” and a consensus price target of $56.71.

Institutional Investors Weigh In On Immunocore

Several large investors have recently added to or reduced their stakes in the stock. Arax Advisory Partners grew its stake in Immunocore by 302.9% in the 4th quarter. Arax Advisory Partners now owns 1,386 shares of the company’s stock worth $48,000 after acquiring an additional 1,042 shares in the last quarter. Osaic Holdings Inc. increased its position in shares of Immunocore by 117.4% during the second quarter. Osaic Holdings Inc. now owns 3,148 shares of the company’s stock worth $97,000 after acquiring an additional 1,700 shares during the period. State of Tennessee Department of Treasury bought a new stake in shares of Immunocore during the second quarter valued at approximately $132,000. Federation des caisses Desjardins du Quebec boosted its holdings in shares of Immunocore by 162.1% in the fourth quarter. Federation des caisses Desjardins du Quebec now owns 5,478 shares of the company’s stock valued at $190,000 after purchasing an additional 3,388 shares during the period. Finally, Cetera Investment Advisers purchased a new stake in shares of Immunocore in the fourth quarter valued at approximately $203,000. 84.50% of the stock is owned by hedge funds and other institutional investors.

About Immunocore

Immunocore plc is a clinical‐stage biotechnology company focused on the development of novel immunotherapies that harness the body’s own T‐cell response to treat cancer and infectious diseases. The company’s proprietary ImmTAC (immune mobilising monoclonal T‐cell receptors against cancer) platform utilizes engineered, soluble T‐cell receptor (TCR) molecules designed to recognise intracellular peptide–HLA complexes. By redirecting and activating T cells against disease‐associated targets, Immunocore aims to address malignancies and persistent viral infections with high unmet medical need.

The company’s most advanced candidate, tebentafusp, is a bispecific ImmTAC molecule that targets gp100, a melanoma‐associated antigen, and has received regulatory approval for the treatment of metastatic uveal melanoma.